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INTRODUCTION
Of all diseases, malaria has been considered
the disease which is most widespread throughout the
world and of the most overall economic importance. Some
two to three million people are estimated to die directly
or indirectly due to malaria each year-(Findlay 1951 a).
Considerably higher estimates have been made in the past,
but where diagnosis becomes more precise, the morbidity
figures for malaria are found to decrease and the figures
for tuberculosis and virus diseases increase. Nevertheless
because of the real importance of malaria, it is natural
that very considerable effort has been expended on develop
ing and perfecting drugs to combat it. The economic
changes likely to result from control are large, and
expenditure on control and eradication is immense both by
national and international organisations.
Much careful thought and planning goes into the
early stage of development and assessment of antimalarial
compounds (Davey 1946 f Wiselogle 1946), It is perhaps
surprising, in view of the large economic factors
involved, how comparatively crude and uncritical have
been many of the late stage assessments of antimalarial
drugs, and in many countries how slow has been the
acquisition of knowledge of the most effective use and
application of antimalarial drugs.
Although mepacrine was first used in the early
1930's (Kikuth and Schonhofer 1935), it was not until
ten years later that it was clearly shown that a
prophylactic regime could be used with confidence
(Fairley 1945) and that when used to cure an established
infection, a high initial dose of mepacrine was definitely
advantageous (Bryant 1942 ; Findlay et al. 1944).
Similarily, chloroquine was first synthesised for
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antimalarial tests in 1934 (Findlay 1951 b), but, even
twenty years later, there was considerable variation in
the dosage recommendations made. As antimalarial drugs
are mainly used amongst peoples with very limited
resources, it is of importance for economic reasons alone
to have precise information on their pharmacology and
activity so that the maximum use can be obtained from the
supplies available to them.
The time taken to decide upon the optimum
prophylactic and curative regimes has been to some extent
due to the difficulty of obtaining human volunteers to
take part in controlled trials and also because of the
confusion that has arisen from the number of tests that
have been carried out and published of which the design
and supervision have not been entirely satisfactory.
Those field tests have often produced conflicting results
and sometimes the authors have drawn conclusions from
their work which their published evidence does not necess¬
arily justify. In those trials which have been carried
out under more standardised conditions, using a mosquito
colony and volunteers, there has naturally been a limitat¬
ion on the number of strains which it has ?oeen possible
to test, but many of the other common sources of error can
be eliminated by such a specialised unit. Where the
results are of major importance, controlled trials with
human volunteers are undoubtedly the most practical way to
>btain evidence rather than impressions.
It is useful to consider the number of sources of
»rror or variation that may occur in conducting a trial of
iny drug, and particularly of an antimalarial drug.
Varying results may be reported and arise from j-
[1) Failure to give the correct drug.
[2) Failure to give the correct dose of drug, or the
opportunity for the subjects to obtain additional
drug exists.
[3) Failure of suitable formulation of the drug.
[4) Abnormal absorption, storage, metabolism or excretion
of the drug.
[5) Variation of immunity of the subjects.
(6) Variation of intensity of infection.
(7) Variation of susceptibility of plasmodial strains
to the drugs.
Frequently, however, the diagnosis of malaria
in the first place is wrong, and I have found this due to i
(1) Badly taken slides (e.g. some parasites from previous
patients may even be adhering in blood clot to the
needle used for spreading a thick blood film).
(2) Erroneous labelling.
(3) Poor stain and technique (e.g. particles from other
positive slides floating off and contaminating
slides in the same staining bath. )
(4) Poor quality microscopes, lighting and micrascopiats.
(5) Failure in transmission of the correct report.
Variations of strain should not be immediately
assumed to be the reason for failure of a drug in
prophylaxis or cure without consideration and preferably
svidence. It must be realised however that strains
varying in their sensitivity to different drugs do exist
md have been shown to exist in certain areas, e.g.
quinine in the Rome area (James et al. 1932), mepacrlne
in Aitaipe-Wewak (Fairley 1946), proguanil in Malaya
(Edeson and Field 1900), pyreraethamine in India
(Chakravarty, N.X., and Chaudhuri, R.N. 1953). I have been
isked to investigate a number of unusual results found in
subjects reputed to be talcing antimalarial drugs. The
irst explanation usually suggested to me was that these
results were due to abnormal strains. In fact, I have
found that usually the diagnosis was incorrect and the
fever was not due to malaria, so that, naturally,
unexpected results were obtained after administering
antimalarial drugs.
In a malarial endemic area, if this subject
becomes of real importance, a useful method of checking
the sensivity of strains is to give at first a very small
dose of the drug under suspicion to some subjects showing
parasitaemia. If there is rapid clearance or sudden
diminution of parasitaemia with what is usually considered
a very small dose of drug, it suggests that the prevalent
/strain ...
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strain is sensitive to the drug and the doses normally
recommended should be effective for general use. Of course
no subject who was seriously ill would be included on a
test of this nature, and, after a blood slide had been
taken on the 3rd or 4th day after the test dose, a full
course of antimalarial treatment would be given. A test
dose equivalent to 200 mgm. of proguanil for adults was
used with satisfactory results on some 60 patients who
r
came for treatment and showed parasitaeraia in Nairobi.
They had come from many parts of (East Africa and had not
;
acquired their infection in Nairobi. After taking a
I
blood slide on the fourth day after dosing, they were
given 600 mgm. of chloroquine base. This was done as a
recrudesence of parasites would otherwise have been prob¬
able in most of the patients after such a small dose of
proguanil. That clearance of parasites had occurred,
temporarily at any rate, indicated that proguanil would
be effective as a prophylactic against the strains
involved. Whether these 60 cases constituted many strains
or substrains of course is not known. Very few facts are
available about the prevalence of strains or substrains of
Plasmodia and their possible variations.
between the wars very valuable investigations
on the chemotherapy of malaria were carried out at the
Ministry of Health Malarial Laboratory at Horton Hospital,
Epsom, principally by James, Sinton and Shute. During the
1939-1945 war, when malaria was causing severe dislocation
amongst Commonwealth troops in the East, a large malaria
research unit was set up and directed by Hamilton Fairley
at Cairns, Australia. There, by carefully designed exper¬
iments and with the aid of volunteers, numerous facls were
rapidly obtained of practical importance in the control
and treatment of malaria. Within a year, more was learned
about the pharmacology and activity of mepacrine in man
than had been learned in the previous ten years. In the
same way, similar large scale but less fundamental trials
were carried out in the U.S.A. in the latter war years.
There, Coatney and Alving have been able to continue work
/in penitentiaries ...
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in penitentaries mainly using P. vivas. But with the
advent of peace, facilities for trials with volunteers
diminished in most countries. Much of the mystery of
malaria had by then been explained, and for those who
could afford them, adequate and reliable drugs were avail¬
able, Nevertheless, those responsible for the care of the
people in poor communities were not yet able to bring the
advantages of freedom from malaria to them all. If
malaria eradication is to be undertaken rapidly, still
cheaper drugs are required, and an even more precise
knowledge of the correct dosage, so that overdosage and
waste can be reduced. Recent reports, as yet unpublished,
from W.H.O. conferences in West and East Africa suggest
that insecticides alone, except in special sites, are
rarely effective, and a greater use of chemotherapy com¬
bined with insecticides is desirable to achieve malaria
eradication.
Imperial Chemical (Pharmaceuticals) Ltd. wished
to examine certain actions of proguanil. They also wished
to investigate other compounds which Davey (personal
Communication) had found were showing important anti¬
malarial activity against P, gallinaceura and P, knowlesi.
A decision had to be reached within a reasonably short
time as to what the place of these compounds might be
amongst established antimalarial drugs. In addition,
there were threats of war in the East and reliable reports
from Malaya of resistance to proguanil in treatment, the
importance and scale of which was then unknown. No exist¬
ing facilities were available within the Commonwealth to
collect this information, so Imperial Chemical
(Pharmaceuticals) Ltd. set up a unit of its own in Nairobi
with the approval of the Colonial Medical Research
Committee, the Director of Medical Services and members of
the Kenya Government.
The work described in the following pages was
carried out at this unit in Nairobi between 1951 and 1955
by myself, but it would not have been possible without
/the cooperation ...
6
the cooperation of many people - Dr. Farnworth Anderson,
Director of Medical Services, Kenya; Dr. A.T.G. Thomas,
M.O.H., Nairobi; Dr. E.J. Foley, Dr. R.B.Heisch of the
Kenya Government; Dr. J. Field, Dr. T. Wilson and
Dr. J.F.B. Edeson of the Medical Research Institute,
Malaya; the War Office, and particularly the staff of the
East Africa Command Royal Army Medical Corps. I received
assistance on different experiments from numerous coll¬
eagues to whom I am greatly indebted, especially
Dr. J.H.D. Roberts, Dr. J.W. McAllan, Dr. R.J. Murray,
Mr. H. Moores, Mr. G.R.C. Van Someren, Mr. H. Jones,
Mr. L. Powell, Mrs, J. Bodington, Mrs, J. Young and
Mrs, E.S. Duncan. From time to time also I received much
valuable help, encouragement and suggestions from my
colleague Dr. D.G. Davey who visited the unit on three
occasions, as well as Sir Neil Hamilton Fairley,
Sir Gordon Covell and Mr. P.G. Shute, to all of whom I am
most grateful. To all the volunteers for their willing
cooperation a very special debt of gratitude is due and an
obligation to ensure that the knowledge acquired at the




A DESCRIPTION OF METHODS
In 1951, work was started at the Imperial
Chemical (Pharmaceuticals) Ltd. laboratory in Nairobi
on testing antimalarial drugs, and, as will be explained
in this section, both non-immune Europeans and Africans
likely to have relatively little immunity acted as
volunteers. To have used only non-immune volunteers
would, of course, have been ideal for our purposes, but
only some 70 men were available. However, we were for¬
tunate in having some 300 Africans likely to have relat¬
ively little immunity who were ready to co-operate on
these tests. As is explained, for certain types of tests
we consider volunteers who may have some degree of immunity
are quite suitable. It must also Le remembered that
probably 98^ of all antimalarial drugs are used by people
who may already have some varying degree of immunity.
Obtaining Infected Mosquitoes t
All the mosquitoes used were from our own
laboratory colony of Anopheles gambiae raised by the
method of Moores (1953). They were infected from patients
for whom fever therapy has been prescribed and in whom the
parasite was carried and passaged by blood or mosquito
infection. Great difficulties were encountered in obtain¬
ing large numbers of infected mosquitoes due to the
variability of infectiousness of different gametocyte
♦carriers*. It was not always possible to obtain a
sufficient number of gametocytes in a 'carrier*, and
further, mosquitoes kept under identical conditions and
feeding on different 'carriers' with apparently similar
gametocyte counts of the saiae strain would sometimes
produce very different infectivity rates. Our experience
led us rarely to feed mosquitoes if the gametocyte counts
were less than 100 per c.ram., but even so, we quite
/frequently failed ...
8
frequently failed to infect a single mosquito in a batch
of several hundred mosquitoes. If the gametocyte count
was less than this, the infection rate of the batches, if
any infection was obtained, was very low indeed. From the
many batches which we dissected, we found nothing to
suggest that subjects with low garaetoeyte counts ever
infected a high proportion of mosquitoes (see also
Muirhead Thomson 1954).
During some five years' work, we have attempted
to obtain infection from about 90 gametocyte carriers.
In spite of this experience, we can lay down no absolute
rules as to how a good infection of mosquitoes is most
likely to be obtained. We could not link our results with
the age of the gametocytes, or whether trophozites were
present or absent, or whether males exceeded females, or
vice versa. On occasions, a gametocyte carrier would fail
at all stages to infect any mosquitoes, though other mos¬
quitoes kept under identical conditions but feeding on a
different gametocyte carrier, would readily become
infected. Our highest infection rate was obtained in a
batch which was exposed to one gametocyte carrier on
Day 1 and 2, and a second carrier on Day 3 and 4, Doth
carriers were infected with a Malayan strain. On sub¬
sequent dissection, all 66 surviving mosquitoes in that
cage were found to be heavily infeeted with sporozoites.
Normally, the salivary glands of the mosquitoes
used were flooded with sporozoites, and unless sporozoites
were seen in numbers and quite readily, the mosquitoes
were classified as non-infected. The batches of mosquit¬
oes which we used to bite volunteers had shown sporozoites
in the salivary glands for at least two days and not more
than sixteen days. (Under our conditions, sporozoites
usually appeared in the salivary glands on the 11th or
12th day after feeding). It has been suggested that
younger or older sporozoites than these may not cause
infection. We had some opportunities to examine this,
and certainly obtained infection from a mosquito whose
/sporozoites ...
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sporozoiteB were unlikely to have been in the salivary
glands for more than one day and also from a mosquito
whose sporozoites were likely to have been in the salivary
glands for at least 26 days, but to be safe we kept within
the times mentioned.
Two abnormalities of sporozoites were encounter¬
ed, and when they were present, the affected batches were
not used for chemotherapeutic trials. On two occasions,
for a period of about a month, we noted that a very high
proportion of the sporozoites were degenerate; they were
short, shrivelled up and curved in appearance. The cause
of this was unknown. On three batches from the same
strain, in different years, we noted the sporozoites
appeared to be sticking together in clumps or rafts.
Sometimes these ♦sticky* sporozoites were slightly narrow¬
er and showed the nucleus more prominently than usual.
We were unable to account for this phenomenon. We found
that infection could be transmitted by mosquitoes in which
the sporozoites appeared to be 'sticky', but we did not
use them in critical tests.
Initial dissections were made of the salivary
glands of a small proportion of each batch of mosquitoes
that had fed on a gametocyte carrier at least twelve days
earlier, to find out if normal sporozoites were present
and were likely to be present in a high percentage of the
batch.
Infecting the Volunteers s
To carry out the experiments, a few mosquitoes
from an infected batch were placed in a small spherical
lamp glass, diameter of about two inches, with mosquito
net covering both ends. The gloss was then held by the
volunteer on his arm or leg and the mosquitoes allowed to
feed for about half-an-hour through the mosquito net cover,
Within a few tainutes, most of the mosquitoes would feed
readily, even in the daylight, provided that they had had




skin considerably, and since sporozoites along with the
saliva and anticoagulant are probably injected during the
probing, the challenge we gave to the drugs can be regard¬
ed as severe. Often, three mosquitoes would leave some
ten or twelve wheals. In natural conditions in a holo-
enderaic area, it is rare to encounter more than 5^ of
female anopheles showing any sporpzoites at all.
Depending on the infectivity of the batch, we varied the
number of mosquitoes in each pot to ensure that whatever
the infectivity of the batch used, two or three were
likely to be infected mosquitoes. ' As mentioned later, for
certain experiments, an even greater number of infected
mosquitoes were used.
After biting, a proportion of the mosquitoes
containing blood were dissected and their infectivity
checked to supplement the details of that batch. Through¬
out these tests, also as a control, a sample of mosquitoes
would be allowed to bite a volunteer not protected by drug
treatment; usually, this was incorporated in the passage
of the strain or as part of the test of a volunteer's
susceptibility to infection.
In our initial test we were able to use batches
of mosquitoes which were about 85-90^ infected. On some
of the later tests we had to include in the batches used
somewhere the infectivity rate was as low as 33^.
The Volunteers t
The African volunteers were chosen from tribes
normally resident in areas where malaria is endemic in
small degree only, if at all, so that, taken as a group,
they were as little immune to malaria as adult Africans
born and raised in Africa are likely to be. The tribes
from which they came have an extremely low incidence of
sickle cell trait. Most of these volunteers were tested,
and none was found to possess the trait. The European
volunteers were all British soldiers who had arrived
recently in Kenya, having previously lived in non-melarioue
territories, and were carrying out normal duties at a
/headquarters ...
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headquarters or hospital unit in Nairobi. There was, so
for as could be found out, no malaria transmission occurr¬
ing in Nairobi at the time of these experiments, as the
malaria control measures there are of a high standard.
The volunteers were seen daily and thick blood
smears were examined and temperatures taken at least once
daily by myself or European technicians. If any man had
any complaints whatsoever, additional examinations were
made. Particular care was taken to see that the entire
dose of the drug under examination was swallowed.
The Infectivity of P. falciparum from One Area for
Mosquitoes from Another :
It is worth recording that we found that our
Anopheles gambiae. originating from the Nyanza Province of
Kenya, was able to transmit the Malayan strains of
P. falciparum with no more difficulty than African strains
of P. falciparum. Jauies, Nicol and Shute (1932) found
that their colony of an English strain of A. maculopennis
could transmit strains of P. falciparum from the South of
Europe but not an Indian strain of P. falciparum. Later,
Shute also failed with that strain of mosquito to transmit
three African strains of P. falciparum. Shute & Maryon
(1951), at the Ministry of Health Malaria Laboratory,
Epsom, showed that A. stephensi from Delhi was an efficient
carrier of a West African strain of P. falciparum, whilst
an English strain of A. atroparvus maintained there vas a
poor carrier.
The Strains of P. falciparum Used t
Throughout these tests, in which we used
artificial infections, we worked entirely with P. falciparum
did so because this species is the most widely spread
species, the most dangerous and, therefore, of the great¬
est overall importance* The early reports of the failures
of proguanil which first prompted this work involved only
P. falciparum, and it is generally true that reported
failures in prophylaxis with most drugs concern only
J, falciparum. P. vivax can be a nuisance when people
/return ...
12
return from malarious areas and stop their prophylaxis,
but it rarely matters in the problem of prophylactic
"breakthrough". It is not without interest that larger
doses of drugs are required to suppress the erythrocytic
forms of most strains of P. falciparum than are required
to suppress most strains of P. vivax.
In the experiments as a whole, use was made of
five "strains" of P. falciparum. Details of these strains
are as follows »-
(t) The Mombasa Strain «
This was our original strain and was maintained
for five years by mosquito and blood transmission. It
was sent to us in Nairobi from Mombasa in response to our
request for blood containing a strain of P. falciparum
found in any patient who was likely to have acquired his
malaria infection in that area. It was transmitted readily
by Anopheles gambiae, and we found that it caused a virul¬
ent infection in patients requiring pyrotherapy, a fact
which was confirmed by Garnham in neurosyphilitie patients
in Europe. (Personal comraunication).
(ii) The Lake Victoria Strain t
This was taken from a patient who was likely to
have acquired his infection on the northern shore of
Lake Victoria.
(iii) and (iv) The Malayan 1 and 2 Strains s
These were sent to us at different times in
heparinised blood from the Tainpin area in Malaya with the
kind cooperation of Drs. Field, Wilson and Edeson of the
Medical Research Institute, Malaya. A request was made
for parasites found to be resistant to proguanil in the
erythrocytic stage, i.e. the infected blood was taken from
patients in whom treatment of a clinical attack of malaria
with proguenil was unsuccessful. We wished to gauge the
degree of resistance in the pre-erythrocytic stage, to
investigate some aspects of the resistance in the mosquitp
cycles, and the cross resistance between drugs. Malayan
No. 1 was also highly resistant to pyremethamine
(Robertson, Davey & Fairley 1952), but Malayan No. 2
did not show this cross resistance to the same degree.
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) The Makueni Strain s
This was investigated at the request of
Dr. S. Avery Jones. He had given a mass treatment of
pyremetharaine, using lOOmg. as a single dose for adults
and with proportionate reduction for children, to all
inhabitants of an isolated village 100 miles from Nairobi
(Avery Jones 1954). One week later, the eighth day, the
blood slides of 100 of the school children examined were
free of parasites, except for one child. Prior to the
dosing, 45^ had shown asexual parasites. This seven-year
old child was given doses of 50 rag, of pyremethamine on
the eighthand again on the ninth day after the initial
dose, but on the fifteenth day asexual parasites were still
numerous. Avery Jones considered it important to find out
whether this one child was showing an abnormal metabolism
of the drug, or a refractory strain was affecting this
one child only in this isolated community where he had „ .
lived amongst the others for several years, Pyrer-ietharaine
had never been used there, and it was thought to be very
unlikely that the child had had even a single tablet of
proguanil, as proguanil had never been supplied to that
village. The strain was subinoculated from the child on
the sixteenth day into a patient requiring pyrotherapy
and mosquitoes were later infected from that patient.
Like all the strains we have used, the virulence of the
strain appeared quite normal and patients required to
have their fever controlled by small doses of quinine or
chloroquine.
The Infectivity of Different Strains of P. falciparum
in the Volunteers i
It is interesting that whether African patients
>f similar origin were infected with an African strain or
i Malayan strain, there was no obvious difference in the
symptoms or course of the malaria, or in the number of
those who required interference with small doses of
jhloroquine or quinine to control the infection. There
were, of course, great variations in the course of the
infection, depending on the origin of the patient and the
degree of endemicity of malaria in his tribal area.
As an example, one neurosyphilitic patient who had been in
hospital for over ten years in Nairobi, where malaria
transmission was virtually not occurring, was infected
with Malayan No, 1 Strain. His thick blood smears showed
a few trophozoites persisting for ten days; he had no
complaints whatsoever, and no pyrexia was noted at any
time. This man came originally from a holoenderaie area
and did not have sickle cell trait. Similar, but slightly
less marked, examples all suggest that if there has been
intensive infection throughout childhood, a very definite
and lasting immunity is built up to a strain of
P. falciparum from several hundred miles away, or even
from another Continent. There are many unexplained reports
of people moving to a new area and soon developing an
acute malaria infection in which a change of temperature
or height is blamed for allowing a recrudescence to occur.
There are also reports that patients living in one
aalarious valley move over the hill to another valley and
there acquire a new infection to which they are reported
as having virtually no immunity. If these observations
are correct, it is difficult to reconcile them with ours.
Thus, in our experiments the different response to infect¬
ion appeared to be much more dependent on the origin and
so on the quantitative degree of acquired immunity of the
patient than on the origin of the strains that were used,
ieinfection with a homologous strain, however, has been
nade to show that a clear cut specificity of immunity can
be produced for all human species of plasmodia (Boyd 1949).
rypes of Causal Prophylactic Experiments i
Most of the experiments fell into two types s—
(1) Multiple session biting type. In this type, a group
sf volunteers, usually four to ten in number, were exposed
to infected bites on many occasions over a period of some
sreeks whilst taking the compound being tested. The
intensity of the infection was arranged to be greater than
ras ever likely to be encountered under field conditions.
Usually, an average of at least one or two
/infected mosquitoes ...
15
infected mosquitoes bit each volunteer daily. With
increased education, with the knowledge that malaria is
transmitted by mosquitoes and with the greater use of
residual insecticides, the proportion of people exposed
to intensive infection is certainly becoming less. In and
around many of the larger towns in tropical countries,
both community and personal measures are taken which have
reduced the opportunity for contact between man and
mosquito. Areas and villages wbere populations are liable
to be exposed to a heavier infection than we induced are
diminishing rapidly throughout the world.
(2) .Single session biting type. In this type of exper¬
iment, the volunteers were exposed to infection on one
occasion only and the drug was given once only at a
definite time in relation to the time of biting. To make
this one challenge severe, we increased the number of
nosquitoes used so that an average of 3-6 heavily infected
mosquitoes bit each volunteer. At first, in this type of
experiment, three volunteers were grouped together and
each given the same dose that required investigation.
As our experience of the immunity likely to be encountered
in the volunteers on these single biting tests grew, we
usually made up a group of one man who was likely to be
very susceptible, and another vho, from his origin, we
might have some doubt as to his degree of immunity but who
was anxious to volunteer for the test. Almost always they
both showed the same outcome; malaria did develop in both
or did not develop in either. Where doubt existed and the
result was important, more volunteers were included. It
was always kept in mind that with a certain dose of drug,
failure of protection was a significant result however few
the failures. Complete protection, on the other hand,
unless the number of volunteers was considerable, required
confirmation.
The drugs we were using on this type of single
biting session tests were of the causal prophylactic type
and all are related to proguanil. The early exo-erythrocytic
forms of P« falciparum are much more sensitive to the drugs
/of this type ...
TABLE I
The action of proguanil against P.falciparum
in single session hi tin.1: tests.
Number of hours
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+ 48 300 2 0 2
* Extracted from Fair ley 194-6.
** Includes one non-immune European volunteer.
*€ "Resistant" strains - see text.
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of this type so far investigated than the erythrocytic
forms. It may be that when the sporozoite is first
introduced into man, its metabolism is slow or insusceptib
to the drugs, but that it becomes increasingly susceptible
at the later part of the early exo-erythrocytic phase when
its metabolism may alter. Thus, a small dose of causal
prophylactic drug given on Day 5 of the early exo-
erythrocytic phase, the fifth after the mosquito bite,
may be effective. If given on bay 2, however, a much
larger dose is required. This may be because the parasite
requires a greater concentration to kill it then, Day 2,
or merely that by giving a large dose there will still be
sufficient drug persisting and available to kill the
parasite at a later more sensitive stage, such as on Day 5,
This was well shown by Fairley (1946) in non-immune
volunteers who were given proguanil at certain times after
being bitten, and we showed it to be true not only of
proguanil (Table I), but of Compound 5943, which may be
described as proguanil with an additional CI. group in
position 3 of the benzene ring, of 10580, a metabolite of
proguanil, and of 10732, which is a metabolite of 5943.
(See Table I).
It can be seen, Table I, that 100 mgm. of
proguanil, when given 24 hours after the volunteers had
been bitten by mosquitoes, was unable to prevent malaria
developing, but when given 48 hours after being bitten,
not only did 100 mgra. prevent overt malaria developing,
but doses as low as 25 or 10 ragm. were also partly
effective. If, however, 300 mgm. was given 168 hours
after these non-immune volunteers had been bitten, malaria
did develop. This result , at 168 hours after exposure,
was because some of the parasites had passed from the
early exo-erythrocytic phase, when they are very sensitive
to proguanil, to the erythrocytic phase, when they are
less sensitive.
The fact that exo-erythrocytic forms of
P. falciparum are most susceptible to drugs of the proguani
type 2 days or more after the entrance of sporozoites and
/least susceptible ...
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least susceptible in their very early life has an import¬
ant bearing on the potential use of the drugs for once-
weekly prophylaxis. It means that a dose to be given
once-weekly must be effeetive,even when it is given at
the time mosquitoes bite, because, if it fails, parasites
can be expected to be released into the blood about
6 days later, i.e. before the next dose is due. It means,
too, that the single biting test can be used to obtain
very quickly knowledge of whether drugs of the proguanil
type will, or will not, be effective for weekly prophy¬
laxis, and the size of the dose necessary. We used this
method considerably in our work.
The bearing of Immunity on Causal Prophylactic Experiments s
It is usually considered that immunity is a
humoral mechanism exerted against the erythrocytic forme
(see the review by Covell, Coatney, Field and Singh 1955).
It can be shown that, when a non-immune subject and a
subject with a high degree of immunity are infected, the
early exo-erythrocytic forms develop normally in each
and parasites pass normally from the tissue to the blood
phase. Once in the blood phase, the parasites in a non¬
immune subject multiply rapidly, especially if the infect¬
ion has been heavy, and overt malaria develops between the
eighth and fourteenth day. A non-immune subject, if
untreated or given minimal treatment, would show
parasitaemia of varying intensity for many months. Any
immunity the subject may possess comes into play to
suppress these erythrocytic forms. If the immunity is
already exceedingly highly developed, the blood forms of
the parasites are suppressed so effectively that, though
present in small numbers, they do not even become visible
in a thick blood film. Frequently, however, intermediate
stages of immunity are found in which parasites become
visible in a thick blood smear, perhaps after a delayed
incubation period and in limited numbers, and parasites
can be found there for only a few weeks. In general, the
greater the immunity the less frequent are garaetocytes
found, though gametocytes are never found during the first
/fifteen days ...
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fifteen days after a mosquito infection with P. falciparum
Where immunity is high, there may be little or no temper¬
ature or symptons and the immunity mechanism is sufficient
to overcome and almost suppress the visible parasitaemia
without the administration of any schizonticidal drug.
This was shown by us amongst men of the Jaluo tribe who
were infected in the course of another experiment design¬
ed and described by Allison (1954). This tribe live in a
holoendemic area and were not, of course, accepted as
volunteers for any tests connected with chemotherapy as
they were likely to have a high degree of immunity. In
those tests it was found amongst those without sickle eel]
trait when exposed to mosquito and blood infection from
a local and a foreign strain (Malayan No. 2) that parasit-*
aemia did actually occur, though it was light and trans¬
ient in fourteen out of fifteen volunteers. In the other
group of this highly immune tribe, who all possessed
sickle ceil trait, parasites never became visible in
thick films in thirteen out of fifteen inen, so that
immunity plus sickle cell trait appeared to have a very
considerable suppressive action on visible parasitaemia.
It is well known that the dose of anti-malarial
drugs of the purely schizonticidal type, such as quinine,
mepacrine, chloroquine, amodiaquine, required to suppress
malaria in a non-immune is larger that that required by a
serai—immune. This must be because the non-immune does not
possess any immunity of his own to have an additive effect
on the suppressive action of the drug.
With drugs which, as well as having some
sehizonticidal activity, have a marked action on the early
exo-erythrocytic forms, such as proguanil, pyremethamine,
5943, 10580, 10732, the problem is rather different. As
we have explained, whether the subject has immunity or
not seems to make little or no difference to the course
of the early exo-erythrocytic forma. If the dose of the
causal prophylactic drug is ineffective, parasites will
be able to pass into the blood. We were interested in
all or none effects. Whether the parasites appear in the
/fclocsd smears ...
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blood smears rapidly and in large numbers within the
normal incubation period, as in the non-immune, or only
in small numbers and perhaps later than the normal incub¬
ation period, as in the semi-immune, is of no account*
i
What id important is that their appearance shows that
parasites have not been eradicated in the early exo-
erythrocytic stage by the particular dose given. To
measure the required dose of a causal prophylactic drug,
therefore, we consider it is of little importance whether
the volunteers possess a moderate degree of immunity or
are non-immunes. Obviously, however, volunteers such as
the highly immune Jaluos, with sickle cell trait, who have
been mentioned above, would foe unsuitable for these tests.
As soon as the first definite parasites were seen in the
blood of these volunteers, we gave a full curative treat¬
ment so that symptoms were reduced to a minimum. The
symptoms sometimes passed practically unnoticed if we had
been particularly diligent in our search and found undoubt¬
ed parasites at a very early stage after they had passed
from the early exo-erythrocytic forms into the blood.
Comparison of Indigenous Africans and Non-immune Europeans
and their Required Causal Prophylactic Pose :
The results Fairley obtained In single session
biting tests, using the causal prophylactic drug, proguanili,
a New Guinea strain of P. falciparum and non-immune
Volunteers gave results very similar to those we obtained,
using proguanil, two East African strains of P, falciparum
and indigenous African volunteers. (See Table I),
For example, when the drug was given 48 hours after
exposure to infection, a dose of 50 ragm, of proguanil was
just able to protect non-imraunes against the New Guinea
strain. When the Mombasa or Lake Yictoria strain was used,
that dose failed to protect 3 out of 4 indigenous Africans,
but 75 jagm, protected 6 out of 7 indigenous Africans
and one non-immune.
Similarly, as is demonstrated in a later section
an 5943, doses of 15 mgm. of 5943, given at the time of
exposure, were able to protect not only numerous Africans
/exposed ...
20
exposed to the Mombasa strain, but two non-immune
Europeans; malaria, however, did develop in one indigen¬
ous African who had taken 10 mgra. of 5943 at the time of
exposure to this strain.
As our experience and knowledge of the response
and susceptibility of volunteers increased, we decided
that we could obtain valuable information by allowing a
group of two or three volunteers to be exposed to infected
mosquitoes on one occasion only, and dosing thorn with the
compound under investigation at a known time in relation
to that exposure. This was simpler than carrying out the
multiple session type of biting experiment. Using the
single session biting test, we found we could obtain a
relatively consistent measure of the minimum causal
prophylactic dose required for these volunteers when
dosed and exposed to infection at specific times* We
could thus obtain information about the rate of
disappearance, due either to excretion or destruction, in
man of these compounds, some of which cannot be estimated
chemically In the blood. We found that if we followed
Fairley's example and established a yardstick, we, or
other workers, could then accurately measure and compare
the response of other strains and other drugs.
For testing schizonticides, of course, this
technique is of little value, because immunity may take
a large share in causing the suppression of the malaria
parasites. There are then two factors involved, immunity
and drug activity, and one of them, the immunity factor,
is variable and virtually immeasurable. Therefore it is
impossible to assess accurately by tests with serai-immunes
the suppressive dose required for non-immunes or serai-
immunes with their varying degrees of immunity.
21
SUMMARY
The methods used in the evaluation of a number
of anti-malarial drugs in man are described and discussed,
including *-
1* The difficulty of obtaining suitable gametocyte
carriers of P. falciparum,
2. The origin of the five strains examined.
3. The carriage of a foreign (Malayan) strain of
P. falciparum by African Anopheles gambiae.
4. The immunity of the volunteers.
5. The suitability of African volunteers •with partial
immunity for eausal prophylactic tests.
6. The advantages of the single session biting test
over the multiple session biting test for
examining causal prophylactic drugs.
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SECTION TWO
THE PROTECTIVE EFFECT OF PROGUANIL
AGAINST AN EAST AFRICAN STRAIN OF
Plasmodium falciparum TRANSMITTED BY Anopheles gambiae
Shortly after proguanil was introduced into East
Africa (late 1946 and early 1947) criticisms were voiced
that it was not always effective in prophylaxis. Much of
the criticism would be best described as hearsay, and it
was virtually impossible to obtain precise facts. The
majority of people appeared satisfied with the drug, but
whether the minority who were dissatisfied were careless
with their medication or were misdiagnosed - "fever" is
all too frequently synonymous with malaria in Africa -
could not be decided. Controlled experiments in volunteer#
were clearly called for, so arrangements were made
accordingly.
The purpose of the experiments was to investigate
the protection afforded by proguanil to subjects regularly
and frequently exposed to the bite of mosquitoes known to
be infected with P. falciparum. The subjects were African
volunteers chosen from tribes normally resident in areas
where malaria is endemic in small degree only, if at all.
In other words, they were as little immune to malaria as
adult Africans born and raised in Africa are likely to be.
Blood smears were taken from prospective volunteers daily
for several weeks before a final selection was made, and
at the end of the experiment, in the event of apparent
complete protection being conferred by the drug,
susceptibility tests were made on those who had particip¬
ated in the experiments.
Most criticism of proguanil in East Africa
emanated from the coastal area, and the reported failures
were concerned entirely with P. falciparum. For these
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experiments, therefore, a strain of this parasite was sent
to us from a patient who had contracted malaria in the
vicinity of Mombasa. Blood taken from this person was
inoculated into patients at a mental hospital who required
fever therapy and the parasite has since been serially
passaged in them. Those showing a suitable number of
garaetocytes were used to infect Anopheles gombiae. This
mosquito is the most important vector of malaria in Africa
but it had not previously been bred in large numbers in
the laboratory and much time had to be given in the
beginning of the work to the establishment of a successful
colony. The methods that led to success have been
described by Moores (1953).
As mentioned earlier, one of the most tantaliz¬
ing features of the work was the procurement of suitable
gametocyte carriers. Not more than about 20 per cent, of
the patients inoculated exhibited what we thought would be
a sufficient number of gametocytes to infect heavily a
high proportion of the mosquitoes that fed. If we used
subjects showing more than about 100 gametocytes per e.mm.{
and allowed the mosquitoes to feed on four or more success¬
ive days, we obtained sometimes an infection rate in the
mosquitoes varying betveen 90 and 100 per cent. Sometimes,
however, patients with very much larger numbers of game¬
tocytes have occasionally failed to infect mosquitoes.
The Plan of the Experiments t
The prophylactic treatments chosen for the
protection of the volunteers are in common use in Africa
and other parts of the world, but emphasis (in the sense
that more volunteers were used on them) was given to
those which might be used for the protection of Africans
themselves. Thirty-five volunteers were arranged in
groups as follows »-
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Group I comprised five volunteers who received
one tablet of 0*1 gramme daily.
Group 2 comprised 10 volunteers who received a
tablet of 0*1 gramme at 3- and 4-day
intervals (they were given one tablet on
the Thursday and one on the Sunday of each
week).
Group 3 comprised 10 volunteers who received
0.3 gramme once weekly (on Wednesdays) and
were bitten every day if possible including
the day on which proguanil was given.
Group 4 comprised 10 volunteers who received
0.3 gramme once weekly and were bitten
every day if possible except on the day
on which proguanil was given.
The distinction between groups 3 and 4 was made
because of the evidence first presented by Fairley (1946)
that the early or primary exo-erythroeytic forms are least
susceptible to proguanil during the first 24 hours follow¬
ing the injection of sporozoites. If the results obtained
in Group 3 had been less satisfactory than those obtained
in Group 4 this might have been the explanation, and it
would have had an important bearing on the use of
proguanil in the field.
The procedure adopted with the four groups,
except for the difference in drug treatment, was the same.
Exposure of the volunteers to the bites of infected
mosquitoes started the day after the first treatment dose
was given, and was continued every day if possible for
2 months* At each biting session, sometimes one, but
usually two or three and, occasionally, as many as five
or six, mosquitoes were fed on a volunteer. The number of
infected mosquitoes available was not always sufficient
to make daily exposure the rule, but rarely did any
volunteer go longer than 2 days without being bitten.
During the 2 months of biting, each volunteer was bitten
by about 100 mosquitoes. Actually, under the conditions
of the experiment, the mosquitoes tended to probe consider
ably, as demonstrated by the number of subsequent wheals,
before really feeding, and since many sporozoites are
probably injected during probing, the challenge to the
drug can be regarded as a severe one, far more severe
than would oecur in most malarious areas.
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The infectivity of each batch of mosquitoes
used in the experiment was checked by dissection and by
allowing a sample of two or three to bite a volunteer,
not protected by drug treatment, during each of the
8 weeks of exposure. Seven of these eight volunteers
developed parasitaemia. The eighti) who failed to develop
parasitaemia within 3 weeks, was later proved to have
immunity. In addition, dissections were made, sooner or
later, of the greater proportion of mosquitoes used in
the experiments, and the point cheeked that sporozoites
were present in the salivary glands. With one exception,
all the batches used were between 95 and 100 per cent,
infected.; about two-thirds of the exceptional batch were
infected but, at the time it was used, three to six
mosquitoes were fed on each volunteer to overcome the
defect.
Treatment commenced the day before the first
exposure to infected mosquitoes, continued throughout the
biting period, and for one week afterwards. There then
followed an observation period of one month,at the end of
which, if nothing had happened, each volunteer was given
his susceptibility test* This test was made by allowing
one or two mosquitoes to feed on each volunteer on two
successive days. The susceptibility test, therefore, did
not offer anything more stringent than the volunteers had
already suffered during the period that the drug was being
administered. Throughout the experiment, thick blood
films were examined daily, and morning temperatures taken,
exeept during the susceptibility test when twiee daily
blood films and temperatures were taken.
The experiment was essentially one to test the
causal prophylactic action of proguanil, i.e. its aetion
against early exo-erythroeytic forms, because it is highly
unlikely that, if the action were only suppressive, the
short after-treatments of two doses of 0.1 gramme (Group 2\




Group 1. At one tisae during the experiment the supply
of infected mosquitoes appeared to be in danger, so the
attempts to infect the five volunteers receiving
0.1 gramme daily were discontinued after an exposure
period lasting 46 days. This group was chosen because
results with the three remaining groups, in which treat¬
ment was less adequate, were excellent.
None of the volunteers in this group ever gave
any evidence of becoming infected and all proved sus¬
ceptible when tested, parasites being found in all of them
within 11 to 16 days of first being bitten.
Group 2. The 56 days of biting and the month's observat¬
ion period passed uneventfully with this group except in
the instance of one volunteer. This man showed parasites
in his blood on the 15th day after first being bitten
and the next day, with still more parasites in his blood,
his temperature was 101,5°". He was then treated immediat¬
ely. We were at a loss to explain this case and suspect
that somehow or other he evaded taking his proguanil.
The incubation period of 15 days falls within normal
limits, and it does not suggest that any drug impeded the
progress of the disease. We tested him again 3 months
later. He was given the original treatment (0.1 gramme
twice weekly) and over a period of 5 weeks he was bitten
every day exeept on 2 days. Altogether, 89 infected
mosquitoes fed on him. The second experiment proceeded
uneventfully, and at its termination he vas shown to be
still susceptible* The success of this second experiment
with him leads us to believe that evasion of treatment vas
responsible for the failure of the first. Subsequent
enquiries and observation pointed to hie being of a
psychopathic personality.
The remaining nine volunteers in this group
never exhibited parasites or symptoms during ths exper¬
imental period and they were therefore subjected to
susceptibility tests. Seven of them gave good responses,
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parasites being found within 10 to 15 days of the first
biting. The other two call for comment. Volunteer No. 3S
was first bitten by four mosquitoes, two on each of two
successive days, all four of which were shown to be
infected by subsequent dissection. No response was
elicited during the next 37 days, and he was then bitten
again by two mosquitoes, one on each of two successive
days. Again there was no response during the next 23
days, and he was finally bitten by three mosquitoes on
one day. fie showed a few parasites 18 and 18 days after
this third biting and thereafter appeared negative. We
regard him as having a very considerable degree of
immunity.
Volunteer No. 9 was bitten on three occasions.
On the first he was bitten by three mosquitoes; 24 days
later by two, and again after 24 days by four. The
mosquitoes used were shown to harbour sporozoites of suit¬
able age, but the volunteer never showed parasites or
symptoms. We regard him as immune.
Group 3. None of the 10 volunteers in this group exhib¬
ited parasites or symptoms throughout the exposure and
observation periods, and they were therefore subjected to
susceptibility tests. Eight of them responded satisfac¬
torily, parasites being found in them within 9 to 20 days
of being bitten. The results in the other two need comment.
Volunteer No. 24 was first bitten by four mosquitoes
(sporozoites were afterwards found in them), two on each
of two successive days, and scanty numbers of parasites
appeared on the 15th and 16th days after the first biting,
but on these two days only. He was bitten again a month
later with one mosquito on one day and two on the next,
and again only seanty numbers of parasites were found on
the 15th and 16th days. He was then treated. We regard
this volunteer as having very considerable immunity.
Volunteer No, 59 was bitten by four mosquitoes
(proved positive), two on each of two successive days,
and showed a few parasites on one day only, 33 days after





































56 days 10 1? 7 0 2
23
Bis first bite. He was bitten again, 31 days after this,
by four infected mosquitoes all feeding on the one occas¬
ion, and again he shoved only a very fev parasites 14 days
later. We regard this volunteer as also having very
considerable immunity.
Group 4. Nine of the 10 volunteers in this group also
remained free of parasites and symptoms throughout the
period of exposure and observation. The exception develop^
ed malaria on the 12th day of the observation period vhich
followed the cessation of biting. This may be an example
of proguanil failing as a causal prophylactic at this dose
(300 mgm. once weekly) and acting only as a suppressive,
but, unfortunately, an unequivocal interpretation cannot
be made. It happened that an accident in the laboratory
some time before had alloved infected mosquitoes to escape
in the Infecting room, and he may have been bitten there
by one of them after he had taken his last dose of proguanil.
He was given treatment with mepaerine (400 mgm. for 2 days]
and proguanil (600 mgm. for 8 days) and then, after a
month during which parasites were never found, he was
subjected to a second experiment. The second experiment
lasted 4 weeks, during which 86 infected mosquitoes fed
on him. Parasites were not found during this time and
during a further 4 weeks observation period. He was then
given a susceptibility test and he showed parasites
14 days after being bitten.
Of the remaining nine volunteers in this group,
two, through circumstances beyond our control, could not
be given a susceptibility test. The seven who were tested
responded satisfactorily.
Discussion t
Of the 35 volunteers used in these experiments
to test the effieacy of various protective treatments with
proguanil, two volunteers were possibly imperfectly
protected. In the case of the first, a volunteer receiving;
0,1 gramme twice weekly, the drug may have failed both as
a causal prophylactic and a suppressive, but for reasons
/already given ...
Clinical Chart A
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Note :—In all the charts the density of the parasites in the blood films is quoted as parasites per oil
immersion field (1/12" objective, x 6 oculars) in a thick blood film. Mosquitoes are described
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Clinical Chart D
-In all the charts the density of the parasites in the blood films is quoted as parasites per oil
immersion field (1/12" objective, x 6 oculars) in a thick blood film. Mosquitoes are described
as positive (+ +) when dissection showed a large number of sporozoites.
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already given we think that failure of the drug is not
the explanation. Instead, in some way or another,
medication was avoided. The second possible failure, in
a volunteer receiving 0.3 gramme once weekly, may be an
example of proguanil acting only as a suppressive at this
dose, but again there were circumstances which preclude an
unequivocal interpretation being given. The element of
doubt regarding the true explanation of each case is to be
regretted, but anyone who has conducted extensive tests
with human volunteers will know how extremely difficult
it is to achieve complete and absolute control of them
at every stage for a long period.
In the remaining 33 volunteers proguanil gave
apparently perfect protection against falciparum malaria.
Susceptibility tests, however, showed that one of the
volunteers was apparently completely immune, and that
three had a considerable degree of immunity. The tests
:ould not be done on two others. These various facts are
summarized in Table II.
There were, then, 27 volunteers in whom the
Irug apparently received a real test. How rigorous it was
depends, of course, on the measure of immunity possessed
oven by these volunteers whom we proved susceptible to the
parasite, and, unfortunately, there is no absolute measure
of immunity. We ourselves, however, have been surprised
by the severity of the malaria induced in many of the
uubjects selected for our work, and we think that the test
Ire hove offered to proguanil has been generally a rigorous
one. We have, whenever possible, avoided making our
volunteers experience unnecessary discomfort, and it was
our purpose when performing the susceptibility tests to
Institute treatment as soon as the presence of parasitesa defini ely co firmed, which meant finding undoubted
parasites in fair numbers on two successive occasions.
Sometimes, however, quite severe symptoms developed before
we had satisfied our requirements concerning parasites,
''hree of the clinical charts (A, B, C) reproduced illus-






in days 9 10 11 12 13 14 15 16 17 18 19 20
Number of volunteers
with the indicated
prepatent period 1 2 6 2 9 2 2 2 1
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■was proved by an accident. A volunteer in Group 3
(he does not appear in the experiment proper described
above because he was replaced) had been subjected to
6 weeks' biting during which he had received six weekly
doses of proguanil 0.3 gramme. Nothing of note occurred
during this period. Then, owing to an error, his seventh
dose was not given. He was bitten on four occasions after
his last dose of drug, and he developed malaria 13 days
after the first of these occasions. His clinical chart
is shown as case D.
Further evidence that our test has been a sound
one is presented in Table 111. This table summarizes the
prepatent periods (time from the first biting to the
appearance of parasites) encountered in our susceptibility
tests, A few of them are prolonged, but the majority fall
•within what are usually regarded as normal limits.
SUMMARY
African volunteers to whom proguanil was being
administered in various dosage regimes were exposed
almost daily for 2 months to the bite of Anopheles gambiae
infected with Plasmodium falciparum. The dosages used
were 0.1 gramme daily, 0.1 gramme twice weekly, and
0.3 gramme once weekly. With two doubtful exceptions




TO INVESTIGATE THE PROPHYLACTIC VALUE OF PROGUANIL
AGAINST A STRAIN OF Plasmodium falciparum
KNOWN TO BE RESISTANT TO THERAPEUTIC TREATMENT
The ability of malarial parasites to develop
resistance to prognanil was first demonstrated with
Plasmodium gallinaceura in chicks (Bishop & Birkett 1947;
Williamson, Bertram & Lourie 1947). Further demonstrations
followed with P. cynomolgi in monkeys (Hawking & Perry 1948;
Schmidt et aL 1949), and finally it was shown by Seaton
and Adams (1949) that P. falciparum and by Seaton and
^ourie (1949) that P. vivas could be made resistant in man.
The early literature has been reviewed by Bishop (1951)
and subsequent papers by Goodwin and Bollo (1955) and
Cove11 et al. (1955).
The early demonstrations were all made under
extremely artificial conditions. Infections in which
parasites were numerous and multiplying freely were first
treated with amounts of proguanil that barely impeded
their progress in any way, and then, during successive
passages of the infection, the amount of drug used in the
treatment was progressively increased. Under such condit¬
ions, resistance usually appears in about three months.
It was also shown that the drug-resistance survived the
sexual cycle in the mosquito. Resistance was measured in
these experiments by the response of the blood parasites
to treatment, but it can be demonstrated, at least in the
case of P. gallinaceum, that a resistance developed by the
blood parasites is transferred to all stages in the life
history. Thus, proguanil is without causal prophylactic
action against a strain to which the blood parasites have
been made very resistant (personal observations), and such
/a strain ...
TABLE IV
Results from the Tampin Clinic, lialaya,
on the Treatment of malaria with pro,-;uaail.
P.falcipamm.
Year Dosage No.cases treated No.failures
194-7-8 100 mg. x 1 26 0
194-7 300 mg. x 1 34 0
194-7 300 nig. x 5-7 32 0
194-8 300 Big. x 1 26 0
194-8 250 .ag. x 1 15 4
194-8 300 mg. x 5-7 2 0
1949 250 Eg. x 1 43 10
194-9 300 rag. x 1 31 7
194-9 500 Eg. x 1 5 1
250 mg. x 4
194-9 300 mg. x 5-7 24 11
1950 300 mg. x 5-7 69 34
1951 300 mg. x 5-7 32 20
1952 300 mg. x 5-7 23 11
1952 400 mg. x 5-7 20 12
1952 600 mg. x 5-7 28 12
P.vivax.
I947-49 300 mg. x 1 31 0
1947-49 300 mg. x 5 9 0
1948-49 100 mg. x 1 17 0
1950 300 mg. x 5 4 0
1951 300 mg. x 5-7 36 2
1952 300 mg. x 5-7 11 1
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a strain ean also be transferred to tbe mosquito from
chicks still receiving drug and normal development of
sporozoites will occur. (Bishop and Birkett 1948)*
The apparent ease with which malarial parasites
can be made resistant to proguanil under laboratory condit¬
ions prompted Field and his colleagues in Malaya to look
for resistance amongst a mixed population of Malayans
and Chinese vho had been given proguanil, probably in
irregular fashion, for some years. This they did at their
experimental malaria clinic in Tampin. When proguanil was
first introduced into Malaya (late 1946) overt attacks of
malaria in the natives were successfully controlled at
this elinic with single doses of 100 mgm. Success with
this treatment continued to be achieved for more than a
fear, but then, in October 1948, occasional patients were
encountered who failed to respond to the single dose
treatment, although a more extended treatment was effect¬
ive. Still later (early 1949), cases were obtained which
failed to respond to full therapeutic treatment (300 mgm.
to 600 ragm. a day for T days). Treatment was described as
failing if parasites were still present on the seventh day
or if earlier interference with another drug was necessary.
Resistance was first found- with falciparum malaria and
later with vivax malaria. A summary of all the results
obtained in the Tampin elinic up to November, 1952, which
were received through the courtesy of Dr. J, Field,
Dr. T. Wilson and Dr. J. F. Edeson is given in Table IV,
(See also Bdeson & Field 1950; Wilson, Munro & Hichard
1952; and the annual reports of the Institute for Medical
Research, Malaya, for 1951-1954).
It is an interesting fact that throughout the
years when resistance to proguanil was clearly developing
there was no indication that the drug was failing
appreciably as a prophylactic. In other words, the
incidence of malaria on the plantations where it was being
used continued to remain low and, consequently, one is
tempted to think that the resistant strains discerned in
/individuals ...
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individuals were strains which developed in them themselves;,
and were not necessarily transmitted to them.
The results of Field and his colleagues, however,
caused some disquiet among the Army authorities because of
the number of troops then operating in malarious areas,
and it was, therefore, decided that experiments should be
done to determine the hazards involved for personnel
taking proguanil for prophylaxis in areas where strains
exhibiting resistance to treatment with this drug might
be carried by mosquitoes.
Experimental s
The work was made possible through the co¬
operation of the Medical Research Institute in Malaya
who sent a proguanil-resistant strain of P. falciparum
to Nairobi, and of the War Office who allowed British
volunteers of the East African Command to be used.
The strain sent from Malaya had resisted a full
therapeutic treatment with proguanil (400 mgm. daily for
more than six days) in the Chinese patient from whom it
was taken. It was dispatched as parasited blood which
was kept cold with ice in a thermos flask, and in Nairobi
the blood was injected into patients for whom fever
therapy had been prescribed. One of them proved a
suitable gainetocyte carrier and a number of Anopheles
gambiae was fed on him. When the mosquitoes became
infected they were used for the attempted infection of
ten British Army volunteers.
The majority of the volunteers had only recently
arrived in East Africa and none had any history suggest¬
ing he ever had malaria. It was planned to expose them
to infected mosquitoes daily for 28 days. The prophy¬
lactic treatment given was 100 mgm. of proguanil daily,
starting on the first day of exposure to infection and
continuing for 14 days after the last exposure. A total
of 42 doses was therefore administered to eftch volunteer
who completed the course. The volunteers were then
observed for a further six weeks.
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A total of approximately 50 mosquitoes fed on
each man. They were seen to probe on several occasions
before engorging; often, nine or ten wheals would be
seen after the feed although only two mosquitoes out of a
pot of four may have engorged. As sporozoites are
contained in the saliva, and some saliva is probably
injected at each time of probing, the infection to which
these volunteers were exposed was very heavy. Dissections
were made of 213 mosquitoes from the batches used, and
91 per cent were found to be infected. Five controls were
used at different times in the experiment, each being
bitten by two mosquitoes, and all developed overt malaria.
Results s
Six of the ten men were protected and completely
fit throughout the twelve week period of experiment and
observation. One man showed parasites on the 15th day
and developed overt malaria on the 17th day. Two men
showed parasites on the 27th day and developed overt
malaria on the 28th and 30th days respectively.
A fourth man shoved parasitaemia on the 45th day, three
days after proguanil administration had ceased, and was
treated with chloroquin at once.
Discussion >
The experiments described above were planned in
1951 because of the anxiety amongst those responsible for
the health of the troops and of the workers on the estates
in Malaya which was being aroused by talk about proguanil
resistance. They were completed in 1952 but, for various
reasons, the results could not be published immediately.
They formed part of a larger programme of work, part of
which will shortly be described in a series of papers,
and incidental to them it was shown that one strain, at
least, of P. falciparum resistant to proguanil - the
strain used in these experiments - was ftlso resistant to
pyrimethamine (Robertson, Davey & Fairley 1952).
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Anxiety concerning resistance to proguanil is
now being -voiced again, Laing (1056) has been able
(as we were) to infect mosquitoes by feeding them on
patients carrying a strain of F, falciparum resistant to
proguanil while the drug was still being administered
and he concludes t "This extension of proguanil resistance
to gametocytes of P, falciparum may seriously detract from
the usefulness of the drug, as proguanil-resistant strains
can thereby be directly transmitted by the mosquito.
In Malaya, proguanil is still extensively used as a
suppressive drug, particularly by Military and Police
forces; its use in the future in preference to other
antimalarial drugs would appear to have an element of
uncertainty."
It seems to us that the implications in this
statement err on the side of pessimism. Proguanil was
introduced into Malaya in 1946; resistance could be
demonstrated to exist in some people in 1948 (see Table IV
and perhaps in a somewhat higher proportion subsequently,
but even now, almost ten years later, there is no evidence
that proguanil fails appreciably as a prophylactic drug
in the territory, and it continues to be used by large
numbers.
Why resistance has not caused proguanil to fail
more is a matter for surmise with our present knowledge.
It appears probable that resistant strains arise in
individuals who practise very irregular prophylaxis or who
treat themselves inadequately when they feel feverish.
Thereafter, the transmission of the strains may proceed
only slowly because adults are often poor "carriers".
Finally, as we have shown above, the exo-erythrocytic
forms are more susceptible than the blood forms, and a
strain exhibiting marked resistance therapeutically may
be controlled in great measure prophylactically. It must
also be of importance that where proguanil is used prophy¬
lactically, the use of other drugs, such as chloroquin,
is advised for treatment, and resistant strains or
incipient resistant strains may thereby be eliminated.
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CONCLUSIONS AND SUMMARY
A strain of Plasmodium falciparum which, for ail
praotioal purposes, was completely resistant to
the therapeutic action of proguanil was controlled
in large measure prophylaciically through the
action of the drug on eaco-erythrocytic forms.
The test to which proguanil was subjected was a
most stringent one - there can be few malarious
areas where so many infective bites would be
given daily - and it is clear, therefore, that
before there can be a wholesale breakdown of the
protection given by the prophylactic use of
proguanil, the strain must be very resistant and




OF 50 mgm. OF CHLOROyUINE BASE DAILY
IN BRITISH TROOPS EXPOSED TO INFECTION
WITH Plasmodium falciparum
Commencing in 1948, evidence began to accumulate
that in the Tarapin area of Malaya larger doses of proguaniH
were required in the treatment of infections with
P. falciparum and P> vivax in the indigenous population
than had been required when the drug was first introduced,
and it was concluded that strains resistant to it were
emerging. (See the reports of the Institute for Medical
Research, Malaya, for 1951 et sec.) When these results
became known, people expressed some anxiety that, if the
resistant strains spread, proguanil might become less
effective as an antimalarial prophylactic not only on the
rubber estates in Malaya but also for the armed forces
then operating extensively in the territory. Subsequent
history in Malaya gave no indication that resistance to
proguanil was in fact spreading, or at least there was no
indication that proguanil was failing to give very effect¬
ive protection against malaria to workers on the estates
and to the troops of the Imperial Army. Actually, the
incidence of malaria amongst service personnel in Malaya
during the recent emergency is probably the lowest ever
recorded for any force operating in a malarious area.
However, when the outcome in Malaya regarding
the efficacy of proguanil was still uncertain, it was
considered wise to make preparations for an alternative
drug to be used in the armed forces, should the need ever
arise. The obvious alternative was chloroquine but, apart
from the obversations of Fairley (see below), no
/information ...
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information was available regarding the use of chloroquine
in daily doses as a suppressive, and it is a daily dose
which the Imperial Army will wish to use.
Experimental t
Fairley (1946) reported that in volunteers
heavily infected with P. falciparum (they were each given
17-18 infective bites) symptoms of malaria failed to
develop and parasites were never found in thick blood
smears whilst they were taking chloroquine in doses of
0«1 gramme daily or subsequently. Similar results were
also obtained in a few volunteers with dosages of 50 mgm.
of chloroquine daily.
Further tests of the lower dose were desired,
and arrangements were therefore made to expose non-iramune
Dritish Army volunteers to the bites of mosquitoes
(Anopheles gamblae) infected with P. falciparum. Twenty
volunteers were used. The dose investigated was 50 mgm.
given daily from the first day of exposure until 14 days
after the last day of exposure. No loading dose was
included because we thought it important to determine if
it could be avoided. In these days of rapid air travel
and sudden preparations, it would be of great adminis¬
trative convenience if antimalarial prophylaxis with
chloroquine, as with proguanil, need not be started till
the day of arrival in a malarious area. There is,
possibly, one slight disadvantage in starting treatment
an the first day of arrival in a malarious area. Any
symptoms of fatigue, headache or alimentary upset result¬
ing from the journey may be wrongly attributed to the
antimalarial drug which has been taken for the first time
an that day. This association may subsequently lead to
some reluctance to take the drug regularly.
Sufficient mosquitoes were not available to give
ill the volunteers an intensive infection simultaneously,
fhree groups were therefore formed and the tests carried
»ut at different times. During the first week,
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approximately 60 mosquitoes bit each volunteer; in
subsequent weeks, about 30 were used on each man. The
infection rate of the mosquitoes was between 33-40 per cent.
The mosquitoes were infected with a specially selected
Malayan strain of P. falciparum known to be resistant to
proguanil, or one of the two £aat African strains that
we call the Mombasa strain and the Lake Victoria strain.
The volunteers were bitten intensively on the
first day of infection, so that the challenge would be
particularly severe at the beginning of the test when
there had been little time to build up a high concentration
of chloroquine within the body. If the drug could resist
the challenge at this early period, then, clearly, it
could be expected to be successful throughout any
subsequent period.
The groups were arranged as follows »-
Eight volunteers were infected for six
weeks with both the Malayan No. 2 strain
and the Mombasa strain. Daily treatment
was given for eight weeks.
Eight volunteers were infected for four
weeks with the Lake Victoria strain.
Daily treatment was given for six weeks.
Four volunteers, although infected for
only one week, were all given an
intensive infection during that week
with the Mombasa strain. Daily treatment
was given for three weeks.
For interest, two other volunteers were
exposed to infection with the Lake Victoria
strain for three weeks, but given proguanil.
They were each bitten by a total of approx¬
imately 65 mosquitoes of which at least
33 per cent were infected. 100 mgm. of
proguanil was given daily, starting on the
first day of exposure and continuing for
seven days after the last day of infection.
An observation period of six weeks was
then made*
Results :
All the volunteers were protected throughout
the experimental period from major malarial symptoms,





(temperatures up to 100-101°F. in two cases, shivering,
joint pains, tender liver and slight headaches) some
8-14 days after infection commenced, but no malarial
parasites could be found in spite of persistent searching
of thick smears. Apart from the routine daily smears,
several additional smears were taken throughout the day
from any volunteers about whom there was any uncertainty.
Neither of the two volunteers taking proguanil exhibited
even minor symptoms.
The symptoms amongst the men taking chloroquine
were possibly due to the abnormally intense infection to
which the volunteers were subjected, because chloroquine
acts only as a schizonticide, the parasites pass
unhindered through the early exo-erythrocytic stage in
the liver, occurring during the first week, and are
killed by the drug when they invade the blood stream
during the second week. The intense infection used must
have resulted in very large numbers of parasites being
killed in the blood stream, and it is thought likely that
the disintegration of such large numbers of parasites was
the cause of the transient symptoms which disappeared
without any increase of dose. It is also possible that




A 50 mgm. tablet of chloroquine base taken
daily acted as a satisfactory suppressive for 20 non¬
immune volunteers infected with one or more of three
strains of P» falciparum. They were protected from all
major malarial symptoms and no parasites were ever found.
The volunteers were exposed to a very intensive initial
infection, followed by a lighter infection for one to
six weeks. The large number of parasites liberated in
the blood at the end of the first week and their
subseqtient destruction by the drug, or the exo-erythrocytic
forms of the parasite in the liver, were considered
responsible for minor malarial symptoms occurring in
several of the volunteers 8-14 days after the start of the
experiment. Two men who received 100 mgra, of proguanil
daily were fully protected, and did not show even minor
symptoms.
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SECTION F I Y £
EXPERIMENTS WITH CIILORO^UINS AND AMODIAuUINE
IN PROPHYLAXIS
It is veil established that 300 ragm. of
chloroquine base once weekly is a reliable suppressive
treatment for all types of malaria. Doses of araotiiaquine
such as 400 or 600 mgtu., have been recommended for use at
fortnightly intervals on the results of field trials
(Singh et al, 1953; Edeson et al. 1955), but there is no
evidence to suggest that chloroquine in fortnightly doses
vould be in any way inferior, t'e considered it important
to obtain a comparison of the activity of the two drugs
under identical and controlled conditions, and also to
establish how low a dose of either might be used to give
a considerable degree of protection to people likely to
have some degree of itsmunity, such as plantation workers.
Immunity to malaria in man seems to be directed mostly,
if not quite entirely, against the blood forms, and
therefore this immunity will assist the suppressive
action exerted by schizonticides such as chloroquine or
amodiaquine, and so a lower dose of drug can be effective
as a suppressive in partially immune subjects than is
required for non-immune subjects.
Experiment I »
Anopheles gambiae infected with P. falciparum
were allowed to feed on a group of ten Africans and were
infected in the same way as we have described previously.
The volunteers were exposed to infection almost daily for
35 days. A total of approximately 80 mosquitoes fed on
each volunteer, and of these 88 per cent were calculated
to be infective (557 mosquitoes were dissected to obtain
/this estimate).
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this estimate). The strain used was one quite foreign to
the volunteers as it was the Malayan Strain No, 2
previously described and selected as being a proguanil—
resistant strain of P. falciparum. The dose used was
150 mgra, of chloroquine base once weekly, which is half
the usually recommended dose. To allow the drug
concentrations to reach a 'steady state* before the
challenge began three doses at weekly intervals were given
prior to the first bite. Three doses were also given
after the last bite to attempt eradication of the infection,
altogether, then, a total of eleven doses were given at
weekly intervals. An observation period of at least
63 days after the last dose was made before tests of the
susceptibility of the volunteers to malaria were carried
out.
lesults : All the volunteers were free from overt
aalaria and fit for work throughout the experimental
period. One man showed very scanty parasites in a thick
film on one occasion. There was no evidence that this
volunteer was unwell and he did not exhibit a morning or
evening pyrexia. Susceptibility tests were carried out
on seven of the volunteers who were still available, and
all were shown to be capable of being infected. Their
incubation periods were,respectively, 11, 12, 12, 12,
13, 13, and 17 days.
Experiment II s
Ten volunteers were exposed for 35 days to the
Malayan No. 2 strain in exactly the same way as described
in Experiment I, but now the dose given was 300 mgm. of
chloroquine base once fortnightly. Two doses at fort¬
nightly intervals were given prior to infection and two
subsequent to infection, making a total of six doses in
all.
Results : All the volunteers were free from overt
malaria throughout the experimental period. One man was
unwell for one day but, almost certainly, all his symptoms
were due to a very mild respiratory infection.
TABLE V
Chloroquine as a suppressive in doses of
130 mgm. weekly.
A
No. of No.of Approx No.dis¬ Suscep¬
Expo¬
sure
doses doses Total No.of sected Result tibil¬
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Several additional thick blood films were taken from him
on that day, and on the next, but no parasites were seen.
Susceptibility tests were carried out later,
and all the volunteers tested were shown to be susceptible
to the strain. The incubation periods of those available
to be tested were 11, 12, 15, 17, and 19 days respectively.
The results of Experiments I and II are summar¬
ised in Table V.
Comment » These tests do not reveal any significant
difference in activity between the two suppressive regimes.
A dose of 150 nigra, once weekly, or 300 mgm. fortnightly,
administered regularly, gave a very useful degree of
protection to subjects likely to have some slight degree
of immunity, even though the intensity of the infective
challenge was high.
It might have been thought that five weeks'
exposure to intense infection and the destruction of
numerous schizonts by schizonticide drugs would have
stimulated the immunity mechanism of these volunteers.
They might be expected to have acquired a considerably
greater degree of immunity than those exposed to a similar
challenge but protected by a causal prophylactic drug.
Causal prophylactic drugs eradicate the early exo-
eryihrocytic forms before they can enter the blood stream
and stimulate the immunity mechanism. I have studied the
prepatent and incubation periods of these men who had been
protected by a suppressive drug and the incubation and
prepatent periods of those groups we have tested for
susceptibility who were protected by causal prophylactic
drugs such as proguanil and 5943. (Thomas, Robertson &
Davey 1953j Robertson 1957). I can find no significant
difference between the two groups. There is no evidence
to suggest that in a short period, such as the period of
this test, a more significant degree of immunity is built
up by the group using a schizonticide as a suppressive
drug, than by the group using causal prophylactic drugs




In this third experiment, a lower dose of
chloroquine was used and its efficiency compared with
that of the same dose of amodiaquine. This time, the
East African Mombasa strain of P. falciparum was used.
The challenge to the volunteers was considerably less
severe than in previous tests because of a shortage of
infected mosquitoes at one period. Some 85 mosquitoes
fed on each man. Of the batches used, a sample showed
sporozoites in 38 per cent (184), and even these were
not so heavily infected as had been found in other
experiments.
Two groups, each of four African volunteers,
were bitten over a period of 56 days. One group was
given 100 nigra, of chloroquine base weekly, and the other
100 nigra, of araodiaquine base weekly. To allow the blood
concentrations of the drugs to reach a 'steady state'
before the attempted infection began, the volunteers
were given three doses of 100 mgm. at weekly intervals
prior to the exposure period. Treatment vas continued
for two weeks after the last time of biting, making
a total of 13 doses.
Results t In the chloroquine group three men were
protected and one man showed parasitaemia on Day 33.
In the aciodiaquine group two men were protected and
the other two had mild malaria symptoms, one of them
showing occasional parasitaemia,
Susceptibility tests were made later, and the
incubation period in days of the volunteers available
for testing were 7, 11, 21 for the chloroquine group,
and 11, 12, 15 for the amodiaquine group.
(Due to a mistake, the man with a 7-day incubation period
was bitten by some 30-40 infected mosquitoes instead of
the 2-4 usually employed for a susceptibility test.)
1
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Experiment IV s
This experiment was carried out at the same
time and in exactly the same way as Experiment III above,
but the two groups were given chloroquine and amodiaquine
at fortnightly intervals. Doses of 250 mgm, (base) of
the drugs were given and the exposure period was 49 days.
Two doses were given prior to infection and two doses
subsequent to infection, a total of eight doses in all
being given.
Results : Three of the men on the chloroquine regime
were free of parasites and symptoms. The fourth had
some malarial symptoms and developed a slightly enlarged
spleen, but definite malaria parasites could never be
detected. The four men on the amodiaquine regime were
free of parasites and symptoms.
Sunnaary of results of Experiments Nos. Ill
and IV are in Table VI.
Experiments Demonstrating the Effective Suppressive
Blood Levels and Persistence of Chloroquine and
Amodiaquine in Non-immune Volunteers t
300 mgm. of chloroquine base has in many areas
been considered a suitable weekly prophylactic regime
for non-immune subjects. We wished to find out if there
was much margin with this dose, so, in addition to the
tests described above, we carried out some tests using
three strains of P. falciparum which were available to
us - our Mombasa and Lake Victoria strains, collected
at random, and Malayan No. 2, specially selected as
showing resistance to proguanil. There is little pub¬
lished evidence to suggest that strains exist which are
poorly susceptible to chloroquine, other than one note
by Messent (IS51) from West Africa, and it has not been
found possible, even in the laboratory, to induce
chloroquine resistant Plasmodia, so the chance of
/encountering strains ...
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encountering strains truly resistant to chloroquine under
natural conditions appears remote* It was only after some
ten years' use of mepacrine that a strain of reduced
sensitivity to mepacrine was clearly shown to exist, the
Aitaipe-Wewak strain. (Fairley 1946), Experience with
other antimalarial drugs suggests that casual reports of
such strains being found should be treated with great
suspicion until the possibility of a technical error has
been very carefully excluded.
Experience with chloroquine suggests that a very
adequate margin of effectiveness is present in the dosage
regimes usually recommended and used at present, both for
suppression and treatment, e.g. the three and four day
treatment courses of 1*2 and 1*5 gramme. We think that in
underdeveloped countries where chemotherapy may be severely
limited because of expense, rather lover doses of chloro¬
quine could frequently be used with little additional risk,
particularly in the many cases where the diagnosis of
malaria may be unlikely but, nevertheless, antimalarial
treatment has to be given as a safeguard. This is clearly
shown by Chaudhuri et al, 1950; Singh et al. 1953;
Wilson & Edeson 1954; Hockenga 1954; and Jeffrey et el.1956,
The tests described below, and shown on Table VII,
were carried out from time to time when non—immune European
volunteers and infected mosquitoes were available. These
tests were planned to establish, after a certain dose, the
period of persistence of a blood level of chloroquine
sufficient to suppress parasitaemia and prevent the para¬
sites multiplying to produce overt malaria. This was done
either by giving a loading dose or giving a number of weekly
doses so that what might be considered the chloroquine
•steady state' was reached. The volunteers were exposed
frequently to the bites of mosquitoes infected with
P, falciparum so that, some six days later, erythrocytic
forms were being discharged constantly into the blood and
being killed or suppressed by the chloroquine present in
/the blood ...
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the blood* Doses were then omitted but the biting continued*
As the drug level fell away, a point was reached where the
chloroquine could no longer suppress the erythrocytic forms
but they survived and multiplied so that overt malaria
resulted. Provided the intensity of infection did not vary
greatly, this period between the last dose of drug and the
onset of overt malaria can be used to compare the excretion
rate and the effectiveness of different drugs, and also any
variation of strains to drugs of the purely schizonticidal
type.
We were not alvays able to ensure a steady and
prolonged exposure period to infected mosquitoes, but,
when there was a shortage of mosquitoes, we timed the
biting period to ensure that erythrocytic forms were being
discharged into the blood well before and after what
experience led us to consider were the critical periods.
Once again, also, we attached rather more
importance to a positive result with the development of
overt malaria than to a negative result where malaria was
prevented. The number of volunteers on each of these
experiments was small and the exposure period was not
always prolonged; nevertheless, the results obtained by
this method give information which could usefully be
amplified by others working on the chemotherapy of malaria
with non-itiraune volunteers.
We show below that two non-immune volunteers put
on to 300 mgm. of chloroquine base weekly on the day
exposure to infection started were protected from malaria,
in spite of receiving no loading dose or build up. (Exper¬
iment No, V). Again, in three volunteers, after a build
up of ten weekly doses of 300 mgm, of chloroquine base,
the doses on two alternate weeks were missed without malaria
developing, (Experiment No. VI), and this vas also found to
occur after only three weekly doses had been given to two
volunteers and the doses for the fourth and sixth weeks
were omitted. (Experiment No. VII).
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Additional teats were made with non-immune
volunteers to demonstrate how long an effeetlwe suppressive
blood level of ehloroquine would persist. It was found
that when exposure was commenced after three weekly doses
of 300 mgm« of chloroqulne, overt malaria developed in
one man eighteen days after his last dose of drug. (Exper¬
iment No. Till). Normally, since one would have expected
overt malaria to develop 8-12 days after the first exposure
to infection, we conclude that sufficient concentration of
drug persisted in the blood to kill or prevent multiplic¬
ation of parasites until just before that eighteenth day.
Another volunteer, after five weekly doses of 300 mgm. of
chloroquine, was then bitten dally for a week, and
parasitaemia developed 33 days after his last dose of
chloroquine. (Experiment No. IX). Similarly, vith
another volunteer, after ten weekly doses of 300 mgm; of
chloroquine base, 33 days elapsed after his last dose before
parasitaemia became evident. Bis period of exposure to
infection was limited to the eighth to the eleventh day
after his last dose of drug because of shortage of
mosquitoes. (Experiment No. X).
As I have mentioned above, experience suggested
that there was little point in exposing any earlier as
parasites appearing in the blood earlier would have been
suppressed by the level of chloroquine present then. In
this experiment, when exposure was on the eighth to
eleventh days after the last dose of drug, one would have
expected overt malaria to have developed some 8-12 days
after the exposure, if an Inactive or non-persistent drug
had been given. In fact, overt malaria did not develop
until 33 days after the last dose of drug had been given.
We consider this delay was due to the suppressive action
of the chloroquine, and only as the blood level of chloro¬
quine slowly diminished were the parasites entering the
blood able to survive and eventually multiply to cause
overt malaria.
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In Experiment No. XII it was found that after a
single dose of 600 nigra, of chloroquine and subsequent almost
daily exposure to infection, overt malaria developed in tvo
of the volunteers on the tventieth day after dosing, and on
the twenty-fifth day in the third volunteer.
Experiment V t
Two non-immune volunteers were given 300 ragm, of
chloroquine base weekly without any loading dose, and biting
was started on the day of the first dose and continued for
three weeks. The biting was heavy, six infected mosquitoes
on the first day, but became lighter (one or two infected
mosquitoes almost daily) during the next eighteen days.
The Mombasa strain was u^ed. A final dose of chloroquine
was given four days after the last bite, making a total of
four doses.
Result t Both volunteers were protected and, in spite of
a follow-up of ten weeks, no malaria developed during that
time.
Experiment VI I
Three men vere dosed at weekly intervals for ten
weeks with 300 mgm. of chloroquine base. Between the ninth
and tenth dose (the sixtieth day) biting was started with an
intensive bite on that day from, approximately, ten infected
mosquitoes, and continued with bites every second or third
day from tvo or three infected mosquitoes until the eighty-
eighth day. The Lake Victoria strain was used. The doses
due for the eleventh and thirteenth veeks vere omitted.
The normal dose of 300 mgra. was resumed for the fourteenth
and fifteenth veeks, after which the experiment was
terminated.
Result » All three volunteers were protected throughout
the experiment.
Experiment VII i
Two volunteers were given three weekly doses of
300 mgra. of chloroquine base. Two days before the third
dose was due they were each exposed to infection with,
approximately, five infected mosquitoes and biting with one
or tvo infected mosquitoes continued almost daily for three
weeks. The doses for the fourth and sixth veeks were
omitted. The normal doses for the fifth, seventh and eighth
weeks vere given, after which the experiment vas terminated.
Result t Both volunteers vere protected throughout.
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Experiment Vill i
Two volunteers were given three doses of 300 nigra,
of ehloroquine base at weekly intervals. Two days before
they were due to receive their third dose they were
bitten by five or six mosquitoes known to be infected
with the Lake Victoria strain and continued to be bitten
almost daily for ten days by two or three infected
mosquitoes. No dose was given for the fourth or fifth
week.
Result a Four days after the fifth weekly dose was due
(the eighteenth day after the third and last dose) overt
malaria developed in one volunteer. It was decided to
treat the other volunteer, though still quite fit, on
that eighteenth day since his last dose of drug.
Experiment IX t
One volunteer was given four weekly doses of
300 mgm« of chloroquine base. Two days before the fifth
dose was due he was exposed to a heavy infection of
mosquitoes infected with our Mombasa strain and the
biting was continued for nine days. His fifth dose of
300 mgra. was given on the day due, and he was then care¬
fully observed to see when the blood level of chloroquine
would diminish to a level that would allow parasites to
multiply and overt malaria to occur.
Result a Overt raalaria developed on the thirty-third
day after his fifth and last weekly dose of chloroquine
tyase.
Experiment X a
A volunteer given ten weekly doses of 300 mgm,
chloroquine base was bitten by five infected mosquitoes
on the eighth, tenth and eleventh day after his last dose
of chloroquine. The strain used was our Mombasa strain.
Result a In this volunteer also overt raalaria developed
on the thirty-third day after his tenth and last weekly
dose of chloroquine.
Experiment XI a
Three other non-immune volunteers were given
600 mgm. of chloroquine base and exposed to a heavy
infection (about ten infected mosquitoes) on that day
and a light infection (one or two infected mosquitoes)
daily for ten days following. The Mombasa and Lake




Result I fwo of these volunteers developed overt
malaria on the twentieth day, and the third on the
twenty-fifth day after the dose.
Experiment XII :
A volunteer was given 300 nigra. of chloroquine
base daily for three days, a total of 900 agm., and he
was bitten heavily an the first day of dosing and lightly
over the next tveaty-eight days vith oar Mombasa strain.
Besalt i A suspected parasite vas seen on the thirtieth
day after the first day of dosing, and overt malaria
developed on the thirty-fourth day.
Aaodiaqaine
Experiment XIII i
Somewhat similar results were found vith a
600 mgra. dose of araodiaquine, carried out in the same
way and at the same time as Experiment No. XI with
ehloroquine. One volunteer developed overt malaria
on the tventieth day and one on the sixteenth day after
exposure to the infection vith the Mombasa strain.
A third volunteer was infected by the Lake Victoria




A dose of 150 mgra. of chloroquino base once
weekly, or 300 ragm. fortnightly, given regularly,
afforded a high degree of protection to 20 African
volunteers likely to have a slight degree of immunity
who were exposed to a heavy infection with a Malayan
strain of P. falciparum. Weekly doses of 100 mgm. of
chloroquine and oraodiaqnine and fortnightly doses of
250 ragm. of chloroquine and amodiaquine were given to
four very small groups of African volunteers. These
doses all gave a considerable degree of protection to
these volunteers in good health and on a good diet*
Their infection was rather lighter and was with the
Mombasa strain. The results from these few volunteers
show that there is no margin, so that considerable
symptoms might develop if dosing was at all erratic,
intercurrent infection or malabsorption occurred, or
if any abnormal strains were encountered.
A biological method of estimating the
persistence of an effective blood concentration of
schizonticides is described, and a few results in
non-immune volunteers are recorded. Several of these
tests, involving small numbers of non-immune volunteers,
confirm the reliability of 300 mgm. of chloroquine
base as a suppressive dose. A few tests with amodia¬




EXPERIMENTS WITH COMPOUND 594-3
Following the discovery of proguanil and during
further development work on the biguanides, the compound
5943 (Formula I) was syntheaised and found to be more
active than proguanil (Curd, Davey, Hendry & Rose 1950).
Some clinical work was also done with it (Chaudhuri,
Rai Chaudhuri & Butta 1952 j Murgatroyd, F, Personal
Communication) which showed that, although effective in
smaller doses, its advantages over proguanil were not
considerable.





At that time, facilities were not available to study its
causal prophylactic action, i.e. its action on early
exo-erythrocytie forms or its oocyst inhibiting property.
It was the main purpose of the present experiments to
remedy these omissions.
Action of 5943 on the Early Eso-erythrocytic Forms of
Plasmodium falciparum i
Experiment I I
Using our standard methods, a group of six
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infection with the Mombasa strain of P. falciparum for a
period of 28 days. Each volunteer was bitten by about
70 mosquitoes. Two hundred and sixty mosquitoes from the
batches used on this experiment were dissected, and
78 per cent, were found to be infected. The first dose
of 20 mgts, of 5943 was given on the first day of exposure
to infection (Day 1). This dose was given thereafter at
weekly intervals for a total of five doses, the last dose
being given on Day 29. An observation period of at least
63 days after the last dose was allowed before suscep¬
tibility tests were made.
All six volunteers were completely protected
throughout the experiments and no parasites were ever
observed in any of them. In subsequent susceptibility
tests they were shown not to be immune. The incubation
periods for the six men were respectively 10, 12, 13,
13, 14 and 17 days.
Experiment II »
This test was carried out in exactly the same
way as Experiment I, except that the weekly dose used
was only 10 ragm.
Of the six men exposed to infection, five were
completely protected but one developed parasitaemia on
Day 21,
Susceptibility tests were carried out in the
five in whom no parasites were found and they were shown
not to be immune. The incubation period in these
volunteers was respectively 11, 11, 11, 12 and 13 days.
The results of Experiments I and II are
summarised in Table VIII,
The results described above shoved that 5943
had considerable promise as a prophylactic drug, and,
therefore, further more detailed studies of it were
/made ...
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- 168 hours 60 mgm. 3 2 1
50 6 3 3
40 1 0 1
30 1 0 1
25 1 0 1
- 144 hours 50 mgm. 2 2 0
25 2 2 0
- 120 hours 50 mgm. 1 1 0
25 1 1 0
- 96 hours 50 mgm* 2 2 0
25 4 2 2
- 72 hours 50 mgm. 1 1 0
25 7 6 1
- 48 hours 50 mgm. 1 1 0
25 5 5 0
15 1 1 0
- 24 hours 25 mgm. 2 2 0
20 2 2 0
15 1 1 0
0 hours 75 mgm. 1 1 0
50 5 5 0
50 1 1 0
25 4 4 0
20 6 6 0
15 10 10* 0
10 15 14 1
7.5 5 4 1
5 3 2 1
+ 48 hours 20 mgm. 2 2 0
10 2 2 0
5 1 1 0
2.5 2 2 0
+ 120 hours 5 mgm. 4 4 0
1 3 3 0
* Includes 2 non-immuaes.
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made by carrying out single biting tests as described
above using the Mombasa and other strains. In these
tests* mosquitoes from infected batches were allowed to
bite volunteers on one occasion only. The volunteers,
at some definite time previously, had taken a single
dose of the drug, or would do so at some definite time
later. Such tests give an indication of the persistence
of the drug and the times at which the parasites are
most susceptible to it. The results are recorded in
|Tables IX and X,
I
We attach considerable importance to tbe results
recorded in Table IX. The life cycle of P, falciparum
is such that parasites are liberated into the blood
about 144 hours after the injection of sporozoites.
(Fairley 1945, 1947; Shortt, Fairley, Covell, Shute and
Garnham 1949). To achieve causal prophylaxis a drug must
completely prevent the release of parasites into the
blood by killing all the early exo-erythroeytie forms.
It has been emphasised previously (Robertson 1957) that
a small dose of causal prophylactic drug given late in
the early exo-erythroeytic phase may be as effective as
a large dose given early in the early exo-erythrocytic
phase. At the time of a once-weekly treatment early
exo-erythrocytic forms may be anything from a few minutes
to some 144 hours old. Effective treatment must therefore
kill all stages, or the properties of the drug must be
such that it persists sufficiently long for a lethal
concentration to be still present at the time when the
parasites become most susceptible to it. For example,
from Table IX we see that with 5943 a dose such as
7,5 or 19 mgm. given at the time of biting did not
always protect, but when a dose of 5 or even 1 mgm. at
120 hours after biting was given, no malaria developed.
Similarly with proguanil, a smaller dose given at
96 or 129 hours after exposure is considerably more
/effective ...
TABLE X














0 hours 12.5 mgm. 1 1 0
10 mgm. 1 0 1
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effective than a larger dose given at the time of
exposure or 24 hoars afterwards. The results we have
obtained with 5943 at —24 hours and 0 hours indicate
very strongly that 5943 in a dose of 29 mgrn, vould be
effective in preventing people from becoming infected
with P. falciparum if it were given ©nee-weekly, and
they give more than adequate confirmation of the results
achieved in Experiments 1 and II.
In order to ensure that the early exo-
erythrocytie forms encounter a lethal concentration of
drug, it is essential that, on leaving a malarious
area, drug administration does not at once cease, but
that at least one further weekly dose is administered
to kill any early exo-erythrocytie forms of P. falciparum
arising from a bite received on the day of leaving the
area. (Unless treatment is given with Primaquine,
malaria caused by P» vivax may, of course, occur many
months after ceasing prophylaxis with any drug.)
In contrast, from these results it can be seen
why, before entering a malarious area, no prior dosing
or build-up is required when a drug of the causal
prophylactic type is used. In practice, however, the
drug is sometimes administered first a day or tvo earlier,
so that symptoms sueh as headache, nausea or tiredness,
due to the upheaval of a journey, are not erroneously
attributed to and associated with a drug whose first
administration coincides with the day of arrival in a
foreign country.
Action of 5943 on the Erythrocytic Stage t
Twenty-five out-patients and 24 in-patients
at different hospitals, showing parasitaemia and fever,
were given treatment with 5943. Though no patient vho
was dangerously ill was given the drug under test,
TABLE XI







Day 1 15 16 17 18 19 24 29
eight lbs. 139 133 123 128
Max. Temp. 98.6 104.5 100.2 99.4 98.4 90.4 98.4 102.4
Trophozoites
cmm.
— 150 L50 6 0 0 0 1200
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many of the patients were suffering from acute malaria*
The patients included people who had coae to Nairobi
from all over East Africa, so that a -variety of strains
were possibly involved. Most of the parasites were
P, falciparum, but some patients were infected with
P. vivas and P. malariae.
We did not fail to achieve clearance of
trophozoites and subsidence of pyrexia within four days,
usually within two, using doses such as 30 mgm, for
adults and 10 ragia* for young children. The number who
showed a recrudescence of parasites two or three weeks
later, however, was considerable. This indicated that
though the dose, as expected, was inadequate, the para¬
sites were all susceptible to the drug, as shown on
Table XI.
Toxic Action of 5943 s
Six healthy men, weighing between 60 and 70
kilos, were given 50 mgm. of 5943 once weekly for nine
weeks, followed immediately by 50 ragm. twice weekly for
a further five weeks. On detailed questioning, one man
thought that on the higher dose he had a tendency to
have looser stools but was by no means convinced of this.
Towards the end of the test, one man developed a few
lichenoid papules ou his forearms. These disappeared
shortly after the test was finished. The opportunity
to readminister the drug was not possible. The
remaining four men remained well throughout. In none
could significant renal or haemopoietic changes be
noted. One patient suffering from chronic discoid
lupus erythematosa received 10 mgm, of 5943 daily for
six months, and five others who had not responded to
other antimalarial drugs received 20 mgo, daily for
three months, omitting doses on Saturdays and Sundays,
No definite side effects were noted. In most patients,
TABLE XII















- 168 hours 50 mg. 2 0 2
0 hours 80 mg. 2 0 2
60 mg. 2 0 2
40 mg* 2 0 2
20 mg. 1 0 1
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the results of treatment with 5943 were not as good as
those obtained by Rogers and Finn (1954) using chloro-
quine, or even aepacrine, in chronic discoid lupus
erythematosia and light eruption.
Resistance i
The results obtained in the early exo-
erythrocytic phase, illustrated in Table XII, confirm
that there is a high degree of cross-resistance with
proguanil against this specially selected Malayan strain.
Results obtained by Avery Jones (personal communication)
in curative theraphy at Makueni indicate that, although
a normal response was not obtained with 5943 against
parasites showing pyremethauiine resistance there, some
therapeutic action was still obtained with it.
Inhibition of Sporozoite Development »
5943, as might be expected, possesses the prop¬
erty of proguanil for preventing the development of the
oocyst in the stomach of the mosquito. One adult,
showing approximately one gametoeyte per field (l/l2th
in objective), allowed mosquitoes to feed on him, and
on subsequent dissection of these mosquitoes, eight in
number, all eight of the survivors were found to be
heavily infected with sporozoites. Immediately after
these mosquitoes had engorged on him, this volunteer
was given 50 mgm. of 5943, Of the mosquitoes which fed
on him the next day, all twelve failed to show sporo¬
zoites when subsequently dissected. Small batches of
mosquitoes were fed on him on alternate days for a further
14 days and, on dissection at the appropriate time, none
of these surviving 43 mosquitoes showed any sporozoites.
Twenty-three days after dosing, however, yet another batch
of mosquitoes was fed on him and, on subsequent dissection,
two out of five of the surviving mosquitoes were found to
show sporozoites. Throughout these 23 days there was
little variation in the day-to-day gametocyte count.
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SUMMARY AMD CONCLUSIONS
The biguanide 5943 was tested against strains
of P, falciparum and found to have considerable anti¬
malarial activity, with similar qualities to proguanil,
but to be weight for weight more active and persistent.
Against strains of P. falciparum investigated, doses
of 15 mgm. once weekly would be an adequate prophylactic
dose. Doses of 30 or even 50 mgm, once weekly would be
well tolerated and would give a wide margin of effective¬
ness, considerably greater than 300 mgra, of proguanil,




AN ACTIVE METABOLITE OF PROGUANIL
AND AN ACTIVE METABOLITE OF 5943
Results obtained from in vitro work with
malarial parasites caused Hawking to postulate that
proguanil was probably converted in the body to a more
active substance (Hawking 1947} Hawking & Perry 1948).
A metabolite of proguanil more active than the parent
substance, and a similar metabolite of 5943 were later
isolated an synthesised (Carrington, Crovther, Davey,
Levi & Rose 1951; Crowther and Levi 1953). The
relationship of the metabolites to the parent compounds
is shown below. It will be seen that the metabolites
are formed from the parent substances by loss of two
hydrogen atoms and subsequent ring closure.
Laboratory work by Davey with Plasmodium
galllnaceum showed that 10,580, the metabolite of
proguanil, was about ten times more active than
proguanil itscif} and 10,732, the metabolite of 5943,
about ten times more active than 10,580, and therefore
about one hundred times more active than proguanil.
Clearly, such active compounds vere worthy
of trial in man, and it is the purpose of this section
to describe the results achieved with them. Because
10,732 was the more active of the tvo new compounds,
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Compound 10,732 - 10 mgm. daily.





Action of 10,732 on the Early Exo-erythrocytic Forms
of P. falciparum i
Experiment I i
A group of ten African volunteers were exposed
almost daily to infection by our standard methods. The
Mombasa strain was used and the exposure period was
49 days. The dose given to each volunteer was 50 mgm,
once weekly, starting on the first day of the experiment,
which is the day when volunteers were first exposed to
mosquitoes, and the dose was continued for two weeks
after the last bite. There was then an observation
period of 50 days. Each volunteer was bitten by about
125 mosquitoes. Of T89 mosquitoes from the batches used
on this experiment, 711 were found to show sporozoites
on dissection, an infection rate of 90 per cent.
Results t Six volunteers were fully protected from
this heavy challenge; the remaining four developed
parasitaemia, one man on Day 35 whilst still being
bitten, another on Day 48, the last day of exposure,
and the other two on the 15th and 24th days respectively
after the last dose of 10,732,
Experiment 11 I
Another group of ten African volunteers were
infected in the same way for a period of 49 days, but
they received doses of 10 mgm, of 10,732 daily from
the first day of infection and for seven days after
the last exposure. They each received bites from
approximately 125 mosquitoes, and, on dissection of a
proportion (789), 90 per eent* were found to harbour
sporozoites.
Results i All ten volunteers were protected throughout
biting, and none developed malaria during the subsequent
period of observation of at least 50 days.
These results are summarised in Table XIII.
TABLE XIV
















0 hours 50 2 0 2
10 2 0 2
+ 12 hours 10 2 0 2
*. 5 2 0 2
24 hours 5 2 0 2
48 hours 10 2 2 0
5 1 0 1
72 hours 5 1 0 1
96 hours 5 1 1 0
120 hours 5 1 1 0
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Experiment III a
Single biting tests were carried out in our
standard way with African volunteers, the biting and
dosing being done at measured intervals. The results
are given in Table XIV. They emphasise again the great
difference in susceptibility of the exo-erythrocytic
forms according to whether treatment is made at the
time of biting and very shortly afterwards, or later,
such as at 98 and 120 hours. In these experiments with
10,732, a single dose of 5 nigra, gave complete protection
at 96 hours and at 120 hours after biting, whereas a
single dose of 50 mgra. failed when given at the time of
biting.
Comments on Experiments I« II and III i
I have emphasised previously that failure or
success of a drug to give complete protection when it
is administered at the time of biting gives a useful
indication of its value for once-weekly prophylaxis
against falciparum malaria. There is no doubt that
10,732 is a very active drug - witness the success of
single doses of 5 ragm. at certain times in the single
biting experiments (Table XIV) and the complete success
of a daily dose of 10 mgm. (Experiment II) - but,
probably because of failure to possess the requisite
pharmacological properties, for example, persistence,
it fails in doses of as much as 50 mgm. given at the
time of biting (Table XIV) and therefore may fail in
a similar dose given once weekly, as was demonstrated
in Experiment I.
Action of 10.732 on the Erythrocytic Stage t
Thirty-six out-patients, mostly children,
showing parasitaemia, but not always with symptoms
attributable to it, were given 10 mgm, of 10,732,
or adults 30 mgm, of 10,732, as a single curative dose.
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(Symptoms of gastrointestinal disturbance occasionally
followed the administration of 50 mgra,, and this dose
Was therefore considered the maximum for routine treatment)
The parasitaemia, whether falciparum, vivax or malariae,
was affected by the drug and usually disappeared, except,
of course, the gametocytes, within two or three days,
but a recrudescence would often occur some seven or ten
days later showing that, though the strains were sensitive
to small quantities of the drug, it appeared to be rapidly
exereted.
Although a high proportion of good results were
obtained with 10 mgra. of 10,732 in children, a number of
relatively poor results were also obtained, sufficient
to show that a single dose treatment with 10,732 could
not be recommended for use in these out-patient clinics,
for example, two one-year-old children were found to be
still showing large numbers of trophozoites seven days
after treatment with 10 mgm. of 10,732, A third child
af similar age, although becoming parasite-free on the
fourth day after treatment with 10 mgm, of 10,732,
returned on the twenty-first day showing a heavy
sarasitaemia.
Action on Gametocytes t
10,732 did not appear to have any visible
effect on gametocytes, but it affects the cycle in the
^osquito, probably in the same way as proguanil and 5943,
Ay inhibiting the development of oocysts, as the following
experiment shows, A seven-year-old youth, found to be
infected with an unknown Kenya strain of JP, falciparum,
showed few trophozoites but the blood contained about
300 garaetoeytes per c,mm. Mosquitoes were fed on him
and he was immediately given 10 mgm, of 10,732. Six hours
Later mosquitoes were fed, and again 24 hours after dosing.
TABLE XV
Action of 10,752 on Garnetocytes.
10 mg. of 10,732 were given on Day 1, at
10.5 a.m. to a seven year old African








Schizonts in blood - -







Infectivity found 9+++ 5-ve 3+
3-ve
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When the mosquitoes were dissected later, nine out of nine
of those which fed on him prior to dosing were found to
be heavily infected with sporozoitesj five out of five
of those which fed six hours after the drag were found
not infected, and of those which fed 24 hours after the
drag had been given, three were lightly infected and
three were not infected. This experiment again emphasises
how relatively quickly 10,732 is either destroyed or
excreted. See Table XV,
Conclusions on 10.732 s
10,732 is active against the early exo-
erythrocytic and erythrocytic stages of F, falciparum
in man and prevents the development of sporozoites in
the mosquito. It also exhibits action against the
blood forms of P. vivax and P. malariae. It does not
appear to differ qualitatively from proguanil but various
results suggest that the antimalarial action is less
persistent, probably because it is excreted quickly.
Thus t-
(i) Proguanil, given once weekly in what would appear
to be, from the laboratory results against
P. gallinaceum, less than equivalent doses,
gives better protection. With lo,?32, 60 mgnu
once weekly failed to give complete protection,
even though 10 mgm. at 48 hours after biting
and 5 mga. at 96 and 120 hours after biting
were successful, and 10 mgm. daily was
completely successful.
(ii) The experiments with gametoeytes (Table XV)
indicated that 10,732 disappeared from the
blood relatively quickly.
(iii) The recrudescence of parasites in some of the
children in whom there had been an initial
rapid clearance of parasites after dosing
with 10 or 20 mgm. of drug sometimes occurred
rapidly.
TABLE XVI
















0 hours 75 3 1 2
62.5 1 0 1
50 8 1 7
57.5 3 1 2
25 1 0 1
48 hours 50 3 3 0
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Action of 10>580 on the Early Exo-erythrocytic Forma
of P. falciparum i
Because the results achieved with 10,732 were
relatively disappointing and because we thought that
10,580 would be equally disappointing, only a limited
number of experiments, sufficient to confirm our
pessimistic view of this compound, were done with it.
I Experiment IV •
As previously, African volunteers were exposed
to Infection on a single occasion by several mosquitoes
infected with the Mombasa strain and were given varying
doses of 10,580. The results are given in Table XVI.
The failure of the drug to give complete protection in
volunteers who received it at the time they were bitten
indicates that it would not be efficacious for once-
weekly prophylaxis in reasonable doses. We think that
the general poorness of the results are to be attributed,
as in the case of 10,732, to the rapidity with which the
drug is excreted. Better results were obtained if
dosing was delayed until 48 hours after biting.
Some twelve curative tests in out-patients
were made. Again, though the results were sometimes
satisfactory, the proportion of patients having a rapid
recrudescence after doses of 50 mgm. was unduly high,
so that it could not be considered for use as a single
dose treatment.
There was evidence that the Makueni strain,
which was resistant to pyremethamine and somewhat resistant
to proguanil, was also resistant to 10,580. For example,
in the blood of one adult who had had 325 mgo. of 10,580
during one week, large numbers of trophozoites and garae-
tocytes were rresent seven days after the last dose.
Several mosquitoes which fed on him an that seventh day
were later found to be heavily infected.
68
Conclusions a
10,580, as *«s expected, shows some cross-
resistance with proguanil and pyremethamine. It
appeared less active than 10,732. Evidence suggests
that it is also probably excreted rapidly. In a patient
infected with a pyreraethamine resistant strain, who had
large doses of 10,580, mosquitoes could be infected when
exposed to him seven days later. High doses were also
liable to cause gastrointestinal irritation.
SUMMAKK
10,732 and 10,580, metabolites of 5943 and
proguanil, were found to be active antimalarial com¬
pounds, similar in qualities to the parent compounds
in their activity at all stages of the life cycle of
P. falciparum.
They are, however, very rapidly excreted and
because of this are less suitable for use as anti¬
malarial drugs than existing drugs.
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